Pazopanib: Additional Phase II data

Researchers at the Mayo Clinic reported additional data from an open-label Phase II trial in 37 evaluable patients with metastatic, rapidly progressive, radioiodine-refractory differentiated thyroid cancers showing that once-daily 800 mg pazopanib produced 18 confirmed partial responses. Additionally, maximum plasma concentration of pazopanib during the first 4-week cycle of treatment was significantly correlated with radiographic response (p=0.021), which the researchers said may indicate that treatment can be individualized to achieve optimum outcomes. Data were published in The Lancet. ...